Hoechst Aktiengesellschaft

Rainer Obermeier

Rolf Geiger

Jurgen Ludwig

Walter Sabel

Wolfgang Konig

Hubert Mullner

Volker Teetz

Dominique Tripier

Ulrich Grau

Martin Gerl

Bernhard Kutscher

Horst Kessler

Karl Geisen

Paul Habermann

Max Hropot

Klaus Sauber

Peter Crause

Gerhard Seipke

Michael Dorschug

Martin Kramer

Peter Deil

Hubert M/u/ Llner

Wolfgang K/o/ Nig

Ingeborg Salomon

A process for isolating insulin which entails performing high-pressure liquid chromatography with pressure-stable acidic cation exchange material under a pressure of from 1.1 MPa to 40 MPa.

Process for isolating insulin by high-pressure liquid chromatography

Hirudin derivatives can be prepared by the selective enzymic replacement of a part of the molecule with an amino derivative. The hirudin derivatives are suitable for preparing pharmaceuticals having an anticoagulatory effect.

Hirudin derivatives and a process for their preparation

A process for obtaining insulin having correctly linked cystine bridges from a corresponding proinsulin amino acid chain in the presence of mercaptan, chaotropic auxiliaries and at a pH of 10 to 11 is described, as well as the direct conversion of the proinsulin to insulin with the aid of enzymes and direct isolation of the insulin from the reaction mixture with the aid of hydrophobic adsorber resins.

Process for obtaining insulin having correctly linked cystine bridges

The present invention relates to hirudin derivatives which are formed from hirudin or the physiologically acceptable salt thereof and a carrier, to a process for the preparation thereof, and to the use thereof as thrombin inhibitor.

Hirudin derivatives with delayed action

A process is described for obtaining proinsulin possessing correctly linked cystine bridges from a corresponding proinsulin amino acid chain in the presence of mercaptan and chaotropic auxiliary agents and at a pH of 10 to 11, as well as its direct isolation from the reaction mixture using hydrophobic adsorber resins.

Process for obtaining proinsulin possessing correctly linked cystine

A process for the production of an amorphous monospheric form of insulin derivatives is described, wherein the insulin derivative is dissolved in an n-propanol/buffer mixture at a pH of 4.5 to 6.5, an n-propanol content of more than 13% relative to water is established and the resulting solution is subsequently diluted with water.

Amorphous monospheric forms of insulin derivatives

Mixed crystals composed of (a) unmodified insulin, des-Phe-B1 insulin, des-Thr-B30 (human) or des-Ala-B30 (pork, beef) insulin and (b) least one insulin having a basic modification at the C-terminal end of the B chain, preferably composed of human insulin and Arg-B31 human insulin and/or Arg.sub.2 -(B31-32) human insulin. These mixed crystals are obtained by crystallization from aqueous solution within a narrow pH range (from about 5.5 to about 6.9). The mixed crystals show a specific moderately prolonged profile and are suitable for the treatment of diabetes mellitus.

Mixed crystals of insulin and insulin derivatives

The invention relates to a process for the preparation of an insulin derivative of the formula I ##STR1## in which R.sup.1 denotes H or H-Phe, R.sup.30 represents the radical of a naturally occurring L-aminoacid and R.sup.31 represents a physiologically acceptable organic group of neutral or basic character consisting of 1 to 3 .alpha.-aminoacids in which the terminal carboxyl function is present in the free form and which insulin derivative has an isoelectric point above 5.8, which comprises reacting an insulin of the formula I in which R.sup.30 denotes the radical of a genetically codable L-aminoacid and R.sup.31 represents OH or a protective group of the carboxyl function, with a peptide or aminoacid derivatives of the formula R-R.sup.30 -R.sup.31 consisting of 2 to 4 .alpha.-aminocacids, in which the terminal carboxyl function is in free form, in the presence of a trypsin-like endopeptidase at a pH value below the isoelectric point of the starting insulin.

Process for the preparation of insulin derivatives, the B chain of which

The invention relates to a process for the isolation and purification of .alpha.-interferons by (a) dissolution of the interferon-containing crude product in guandine. HCl solution and precipitation by dilution with water and/or (b) by chromatography on an HIC column under renaturing conditions.

Process for the isolation and purification of alpha-interferons

The invention relates to a process for the isolation and purification of .alpha.-interferons generated by plasmids from bacterial cultures which have been modified by genetic engineering, and of .alpha.-interferons from culture supernatants of induced mammalian cells, which comprises partition of appropriate crude substances containing interferon between an aqueous urea solution, which contains a surfactant, and a mixture of n-butanol and glacial acetic acid which contains water, and isolation of the purified .alpha.-interferons from the upper phase.

A method for separating insulin or certain insulin derivatives from mixtures containing the same by chromatography of the mixture on a column filled with silica gel having a particle size between 40 and 500 microns with an eluant mixture comprising chloroform, methanol, water and triethylamine.

Process for the separation of mixtures of insulin, insulin derivatives

The invention relates to a process for the preparation of peptides of the general formula

Process for the preparation of pentapeptides having an action on the

The invention relates to cyclopeptides of the formula I ##STR1## in which A denotes Lys, D-Lys, Arg or D-Arg, B denotes Lys, D-Lys, Arg or D-Arg, C denotes Asp, D-Asp, Glu or D-Glu, U denotes Val or D-Val and D denotes Tyr, D-Tyr, Trp, D-Trp, Phe or D-Phe, 1 to 4 of the radicals A, B, C, U and D being in the L-configuration and the remaining radicals being in the D-configuration, processes for their preparation, their use and peptidic precursors and processes for their preparation.

Novel peptides having an immunostimulating action, processes for their

The invention relates to a process for the preparation of insulins from analogs of preproinsulins, which comprises reacting preproinsulin analogs, at a pH below the isoelectric point of the insulins in the presence of trypsin or a trypsin-like endopeptidase, with an ester of natural amino acids or their derivatives and then cleaving off the ester group and other protective groups which may optionally be present.

Process for converting preproinsulin analogs into insulins

What is disclosed is a method for making human insulin or modified human insulin from pig insulin or modified pig insulin by reacting the pig insulin starting material at a pH below its isoelectric point with an excess of a threonine ester in the presence of trypsin or a trypsin-like enzyme.

Growing community of inventors

Hattersheim am Main, Germany

Rainer Obermeier